950210 — Prestige Biopharma Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapMomentum Trap

Annual balance sheet for Prestige Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.

	2020 June 30th	2021 June 30th	2022 June 30th	2023 June 30th	2024 June 30th
Period Length:	—	—	—	—	—
Source:	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	38.3	407	235	230	165
Net Total Accounts Receivable
Net Total Receivables	2.02	—	—	0.101	0.282
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	41.5	407	241	237	180
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	3.76	5.7	29.7	236	235
Net Goodwill
Net Intangible Assets
Long Term Investments
Other Long Term Assets
Total Assets	133	535	387	565	512
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	7.06	12.4	32.3	103	105
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Minority Interest
Total Other Liabilities
Total Liabilities	18.6	25.8	54	222	196
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
ESOP Debt Guarantee
Other Equity
Total Equity	115	509	333	343	316
Total Liabilities & Shareholders' Equity	133	535	387	565	512
Total Common Shares Outstanding